Clin2
NCT04290663Possibly a fitRecruiting

Radioiodine decision after thyroid surgery for intermediate-risk cancer

Thyroid CancerIntermediate Risk

Part of Cancer, Hormones & metabolism clinical trials.

This study compares two approaches after thyroid surgery: giving radioactive iodine right away versus deciding based on follow-up test results. It aims to see which approach better helps people with intermediate-risk differentiated thyroid cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
368 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have differentiated thyroid cancer (papillary, follicular, or Hürthle cell), not medullary/anaplastic/poorly differentiated, and not NIFTP.
  • Your cancer must be “intermediate-risk” based on specific tumor size/lymph node details and limited spread (and no extra growth outside the capsule).
  • You had total thyroidectomy with all visible tumor removed (no R2/microscopic leftover that counts as incomplete).
  • You had surgery 6 to 10 weeks (about 1–2.5 months) before randomization, and started thyroid hormone (levothyroxine/LT4) at least 6 weeks before enrolling.
  • Your post-surgery neck ultrasound looks normal; if something was unclear, follow-up testing must be negative and tumor marker Tg must be under 10 ng/mL.
  • You have no known distant metastases and you can attend yearly follow-ups for 5 years; performance status must be 0 or 1 (able to do most usual activities).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06980103Recruiting
Decision aid for RAI in thyroid cancer

This trial offers a decision aid to help you choose whether to have radioactive iodine (RAI) treatment after thyroid cancer surgery. You may qualify if you have intermediate-risk thyroid cancer and haven't yet made a decision about RAI.

Washington D.C., District of Columbia
NCT07056218Not yet recruiting
Radioactive iodine therapy for low and intermediate risk thyroid cancer

This trial studies how well radioactive iodine treatment works for people with certain types of thyroid cancer that have a low or intermediate risk of coming back. It aims to see if this treatment is effective and safe for these patients.

NCT06558981Recruiting· Phase 3
Radiation therapy after thyroid surgery for high-risk cancer

This trial is testing whether giving radiation therapy after thyroid surgery can help destroy any leftover cancer cells in people with high-risk differentiated thyroid cancer. It is for those who had surgery but some cancer was still left behind.

Shanghai
NCT06134830Not yet recruiting
Radioactive iodine doses for thyroid cancer

This study looks at how different doses of radioactive iodine affect people with thyroid cancer after they have had their thyroid removed. It may help doctors choose the best dose for future patients.

NCT06524167Recruiting
Radiation therapy after surgery for advanced thyroid cancer

This study looks at whether adding radiation therapy after surgery can help people with thyroid cancer that is at high risk of coming back. It includes different types of thyroid cancer, like differentiated and medullary types.

Shanghai
NCT05733013Recruiting
Using redifferentiation medicines before radioactive iodine for thyroid cancer

This study collects information on how redifferentiation medicines used before radioactive iodine work in everyday care for certain thyroid cancers that are unlikely to respond to radioactive iodine. It may help doctors understand the best real-world way to use these medicines to plan and deliver treatment.

New York, New York

Hear when a new Thyroid Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.